Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.16)
# 1,100
Out of 4,784 analysts
206
Total ratings
42.86%
Success rate
1.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $4.30 | +690.70% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $54.80 | +31.39% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $54.24 | +29.06% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $113.16 | +32.56% | 26 | Mar 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Assumes: Overweight | $175 → $183 | $122.92 | +48.88% | 5 | Mar 7, 2025 | |
| ERAS Erasca | Assumes: Overweight | $4 | $1.52 | +163.16% | 3 | Mar 7, 2025 | |
| IRON Disc Medicine | Assumes: Overweight | $85 | $52.36 | +62.34% | 6 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Assumes: Overweight | $38 → $35 | $8.02 | +336.41% | 6 | Mar 7, 2025 | |
| CTNM Contineum Therapeutics | Assumes: Overweight | $25 | $7.07 | +253.61% | 2 | Mar 7, 2025 | |
| CGON CG Oncology | Assumes: Overweight | $55 | $26.42 | +108.18% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $14.59 | +85.06% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $3.82 | +30.89% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $20 | $17.07 | +17.16% | 24 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $43.19 | +55.13% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $8.43 | +42.35% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $95 | $131.81 | -27.93% | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.48 | +269.20% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $34.73 | +101.55% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.80 | +400.19% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $1.91 | +109.42% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.60 | +566.67% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $4.08 | +3,331.37% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $37.82 | +122.10% | 7 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $8.97 | +345.93% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.64 | +753.66% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.49 | +235.57% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.50 | +100.00% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.05 | +1,233.33% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.77 | +464.02% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $36.70 | -40.05% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $27.65 | +437.07% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $2.09 | +2,770.81% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.65 | +64.38% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.50 | +10,721.64% | 6 | May 8, 2020 |
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $4.30
Upside: +690.70%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $54.80
Upside: +31.39%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $54.24
Upside: +29.06%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $113.16
Upside: +32.56%
Jazz Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $175 → $183
Current: $122.92
Upside: +48.88%
Erasca
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.52
Upside: +163.16%
Disc Medicine
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $52.36
Upside: +62.34%
Cullinan Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $8.02
Upside: +336.41%
Contineum Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $25
Current: $7.07
Upside: +253.61%
CG Oncology
Mar 7, 2025
Assumes: Overweight
Price Target: $55
Current: $26.42
Upside: +108.18%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $14.59
Upside: +85.06%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $3.82
Upside: +30.89%
Mar 7, 2025
Assumes: Equal-Weight
Price Target: $20
Current: $17.07
Upside: +17.16%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $43.19
Upside: +55.13%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $8.43
Upside: +42.35%
Oct 11, 2024
Maintains: Overweight
Price Target: $92 → $95
Current: $131.81
Upside: -27.93%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $9.48
Upside: +269.20%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $34.73
Upside: +101.55%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.80
Upside: +400.19%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $1.91
Upside: +109.42%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.60
Upside: +566.67%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $4.08
Upside: +3,331.37%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $37.82
Upside: +122.10%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $8.97
Upside: +345.93%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.64
Upside: +753.66%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.49
Upside: +235.57%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.50
Upside: +100.00%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.05
Upside: +1,233.33%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.77
Upside: +464.02%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $36.70
Upside: -40.05%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $27.65
Upside: +437.07%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $2.09
Upside: +2,770.81%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.65
Upside: +64.38%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.50
Upside: +10,721.64%